Press Releases

ADC Therapeutics Announces Positive Pre-clinical Results for Two of its Novel ADCs at the American Society of Hematology Conference

ADC Therapeutics Announces Positive Pre-clinical Results for Two of its Novel ADCs at the American Society of Hematology Conference
5 December 2015 Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US – 5 December 2015 – ADC Therapeutics (ADCT), the oncology drug development company, today presented pre-clinical results for both ADCT-301 and ADCT-402, its novel Antibody Drug Conjugates (ADCs) in hematological tumours at the 57th American Society of Hematology (ASH) Annual Meeting, December

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for its Second Novel Antibody Conjugate ADCT-402 against Lymphomas and Leukemia

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for its Second Novel Antibody Conjugate ADCT-402 against Lymphomas and Leukemia
4 December 2015 Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US – 4 December 2015 -– ADC Therapeutics SA (ADCT or the “Company”), the oncology drug development company focused on Antibody Drug Conjugates (ADCs), today announced that it has received clearance from the US Food and Drug Administration (FDA) to begin clinical trials

ADC Therapeutics Announces Expanded Board with Appointment of Highly Experienced Non-Executive Directors

ADC Therapeutics Announces Expanded Board with Appointment of Highly Experienced Non-Executive Directors
28 September 2015 Dr Hans-Peter Wild and Jacques Theurillat join the Board Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US - 28 September 2015 – ADC Therapeutics (ADCT), the oncology drug development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that Dr Hans-Peter Wild and Jacques Theurillat have been

ADC Therapeutics Secures $80m Financing to Progress its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology

ADC Therapeutics Secures $80m Financing to Progress its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology
2 September 2015 Lausanne, Switzerland and London, UK and Murray Hill, New Jersey, US, 2 September 2015 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $80 million through a private placement of

ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer
22 June 2015 Lausanne, Switzerland and London, UK, 22 June 2015 – ADC Therapeutics Sàrl (the Company or ADCT), the oncology research and development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced the appointment of Dr. Chris Martin as its Chief Executive Officer. Dr. Martin was co-founder of Spirogen Ltd and

ADC Therapeutics Presented Positive Pre-clinical Activity of its Novel Anti-CD22 Antibody-Drug Conjugate at the American Association for Cancer Research (AACR) Annual Meeting

ADC Therapeutics Presented Positive Pre-clinical Activity of its Novel Anti-CD22 Antibody-Drug Conjugate at the American Association for Cancer Research (AACR) Annual Meeting
19 April 2015 Lausanne, Switzerland and London, UK, April 19 2015 – ADC Therapeutics (ADCT) today presented the following abstract: “Pre-clinical Activity of hLL2-PBD, a Novel Anti-CD22 Antibody-Pyrrolobenzodiazepine (PBD) Conjugate in Models of Non-Hodgkin Lymphoma” at the 2015 American Association for Cancer Research (AACR) Annual Meeting, Philadelphia, Pennsylvania, USA. Highlights of the data presented include:

ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas

ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas
16 March 2015 Lausanne, Switzerland and London, UK, 16 March 2015 – ADC Therapeutics Sàrl (the “Company”), the oncology drug development company focused on Antibody Drug Conjugates (ADCs), today announced that it has filed an Investigational New Drug application (IND) with the US Food and Drug Administration as it moves its pipeline into clinical development.